Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07493122 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of IMC-S118AI in Type 1 Diabetes

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Immunocore Ltd
7 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 1 Diabetes
886 trials monitored
See 40 trials at risk
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Trial Details
NCT Number NCT07493122
Lead Sponsor Immunocore Ltd
Conditions
(from sponsor)		 Type 1 Diabetes, Type 1 Diabetes (T1D), Diabetes Type 1
Related terms Diabetes Mellitus, Diabetes Mellitus, Type 1
Enrollment 154 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov